血流导向装置治疗颅内动脉瘤后6个月以上失败的管理:一项国际德尔菲共识
该国际德尔菲共识邀请67名专家参与多步骤共识流程,23名(34%)参与。共识涉及血流导向装置治疗后6-24个月动脉瘤持续充盈的管理,包括治疗失败的定义时间点、复查方式及再治疗指征。
要点
- 6个月时动脉瘤增大或持续快速血流定义为治疗失败(96%共识)
- 12个月时动脉瘤增大或出现症状定义为治疗失败(78%共识)
- 24个月时无论大小和充盈特征持续充盈定义为治疗失败(74%共识)
核心结论
- 作者提出了专家在血流导向装置治疗后6-24个月动脉瘤未闭塞管理方面的共识实践。
研究设计与样本
- 国际德尔菲共识流程,邀请67名专家参与,最终23名(34%)参与。
主要发现
- 83%的专家认为表面修饰的血流导向装置不影响双联抗血小板治疗的实施。
- 83%的专家认为仅凭无创影像无法确定内膜增生或装置内狭窄的程度,但仅65%选择数字减影血管造影作为首选方式。
- 6个月和12个月时,若存在持续充盈伴动脉瘤增大(96%、96%)、装置位置不良(48%、87%)或蛛网膜下腔出血史(65%、70%),倾向于再治疗;24个月时若持续充盈且动脉瘤尺寸无缩小(74%),倾向于再治疗。
- 87%的专家倾向于使用额外血流导向装置治疗而非动脉瘤夹闭,83%认为随访原则和91%认为治疗失败原则与首次血流导向装置相同。
关键数值与推荐
- 6个月时若动脉瘤增大或持续快速血流通过整个动脉瘤,定义为治疗失败(96%共识)。
- 12个月时若动脉瘤增大或出现症状,定义为治疗失败(78%共识)。
- 24个月时若持续充盈,无论大小和充盈特征,定义为治疗失败(74%共识)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 邀请的67名专家中仅23名(34%)参与。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The placement of flow-diverting devices has become a common method of treating unruptured intracranial aneurysms of the internal carotid artery. The progressive improvement of aneurysm occlusion after treatment-with low complication and rupture rates-has led to a dilemma regarding the management of aneurysms in which occlusion has not occurred within 6-24 months. The authors aimed to identify clinical consensus regarding management of intracranial aneurysms displaying persistent filling 6-24 months after flow diversion and to ascertain questions that may drive future investigation. METHODS: An international panel of 67 experts was invited to participate in a multistep Delphi consensus process on the treatment of intracranial aneurysms after failed flow diversion. RESULTS: Of the 67 experts invited, 23 (34%) participated. Qualitative analysis of an initial survey with open-ended questions resulted in 51 statements regarding management of aneurysms showing persistent filling after flow diversion. The statements were grouped into 8 categories, and in the second round, respondents rated the degree of their agreement with each statement on a 5-point Likert scale. Flow diverters with surface modifiers did not influence administration of dual-antiplatelet therapy according to 83%. Consensus was also reached regarding the definition of treatment failure at specific time points, including at 6 months if there is aneurysm growth or persistent rapid flow through the entirety of the aneurysm (96%), at 12 months if there is aneurysm growth or symptom onset (78%), and at 24 months if there is persistent filling regardless of size and filling characteristics (74%). Although experts agreed that the degree of intimal hyperplasia or in-device stenosis could not be ascertained by noninvasive imaging alone (83%), only 65% chose digital subtraction angiography as the preferred modality. At 6 and 12 months, retreatment is preferred if there is persistent filling with aneurysm growth (96%, 96%), device malposition (48%, 87%), or a history of subarachnoid hemorrhage (65%, 70%), respectively, and at 24 months if there is persistent filling without reduction in aneurysm size (74%). Experts favored treatment with an additional flow diverter (87%) over aneurysm clipping, applying the same principles for follow-up (83%) and treatment failure (91%) as for the first flow diverter. CONCLUSIONS: The authors present the consensus practices of experts in the management of intracranial aneurysms without occlusion 6-24 months after treatment with a flow-diverting device.
引用
- Chintapalli R, Nguyen S, Taussky P, et al. Management of failed flow diversion for intracranial aneurysm beyond the first 6 months of follow-up: an international Delphi consensus. J Neurosurg. 2024. PMID: 38820616. doi:10.3171/2024.3.JNS2499
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。